Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PADI4 is a member of a gene family which encodes enzymes responsible for the conversion of arginine residues to citrulline residues. Additionally we are shipping PADI4 Kits (14) and PADI4 Proteins (13) and many more products for this protein.
Showing 10 out of 108 products:
Human Polyclonal PADI4 Primary Antibody for WB - ABIN389125
Nakayama-Hamada, Suzuki, Kubota, Takazawa, Ohsaka, Kawaida, Ono, Kasuya, Furukawa, Yamada, Yamamoto: Comparison of enzymatic properties between hPADI2 and hPADI4. in Biochemical and biophysical research communications 2005
Show all 5 references for 389125
Human Polyclonal PADI4 Primary Antibody for EIA, WB - ABIN357799
Wang, Wysocka, Sayegh, Lee, Perlin, Leonelli, Sonbuchner, McDonald, Cook, Dou, Roeder, Clarke, Stallcup, Allis, Coonrod: Human PAD4 regulates histone arginine methylation levels via demethylimination. in Science (New York, N.Y.) 2004
Show all 2 references for 357799
Cow (Bovine) Polyclonal PADI4 Primary Antibody for WB - ABIN2785937
Costenbader, Chang, De Vivo, Plenge, Karlson: Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. in Arthritis research & therapy 2008
No associations were found between clinical subtypes of JIA and PADI4 allele frequency. rs2240337 in the PADI4 gene was significantly associated with anti-cyclic citrullinated peptide antibody-positivity in juvenile idiopathic arthritis.
The effect of the PADI4-104C/T polymorphism on RA risk in the Chinese population was evaluated in a meta-analysis. The overall analysis indicated a significant association between the PADI4-104C/T polymorphism and RA risk in the Chinese population (T vs C: OR = 1.45, 95%CI = 1.18-1.78; TT vs CC: OR = 1.49, 95%CI = 1.24-1.80; TT vs CC+CT: OR = 1.28, 95%CI = 1.08-1.51; TT+CT vs CC: OR = 1.75, 95%CI = 1.30-2.37).
Overexpression of PAD4 constrains the activity of EMT (show ITK Antibodies) via suppressing Elk1 (show ELK1 Antibodies) expression.
Our study also demonstrated that PADI4 contributes to tumor metastasis by regulating the gene expression of insulin-like growth factor 1 (IGF1 (show IGF1 Antibodies)) and WAS/WASL-interacting protein family member 1 (WIPF1 (show WIPF1 Antibodies)).
PAD4 levels were significantly higher in patients with rheumatoid arthritis than in patients with systemic lupus erythematosis or healthy controls. Anti-PAD4 antibodies were detected in 30% of patients with rheumatoid arthritis, but not in patients with SLE, systemic sclerosis or controls.
This meta-analysis showed that the PADI4 -94G/A variants may influence RA risk in the Chinese population.
The results highlight an association between PAD4 and DNA hypermethylation in acute promyelocytic leukemia (show PML Antibodies) and demonstrate that targeting PAD4 or regulating its downstream effectors may be a promising strategy to control differentiation in the clinic.
We identified the presence of PADI3 (show PADI3 Antibodies) mRNA expression in synovial tissue and PADI2 (show PADI2 Antibodies) and PADI4 mRNA expressions in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Polymorphism in exon-4 of PADI4 gene showed significant association with rheumatoid arthritis (RA)and polymorphism in exon-3 exhibited moderate association with RA.
PADI4 rs1748033 gene polymorphism increased the risk of RA in a sample of the Iranian population.
a role for NETs in cardiac fibrosis and conclude that PAD4 regulates age-related organ fibrosis and dysfunction.
PADI4 exacerbates arthritis with diverse immunological modifications.
Selective inhibition of peptidylarginine deiminase IV with Cl-amidine blocked NET formation, reduced atherosclerotic lesion area, and delayed time to carotid artery thrombosis in a photochemical injury model.
Padi4 is part of the pluripotency transcriptional network, binding to regulatory elements of key stem-cell genes and activating their expression
PAD4 regulates the proliferation of multipotent progenitors in the bone marrow by controlling c-myc (show MYC Antibodies) expression.
PAD4-mediated chromatin decondensation in the neutrophil is crucial for pathological venous thrombosis and present neutrophil activation and PAD4 as potential drug targets for deep vein thrombosis.
PAD4 is dispensable in this effector phase model of arthritis
analysis of regulation of histone modification and chromatin structure by the p53 (show TP53 Antibodies)-PADI4 pathway
An increase in citrullinated proteins resulting from increased PAD2 and 4 is an important change in the pathogenesis of multiple sclerosis.
This gene is a member of a gene family which encodes enzymes responsible for the conversion of arginine residues to citrulline residues. This gene may play a role in granulocyte and macrophage development leading to inflammation and immune response.
peptidyl arginine deiminase, type IV
, protein-arginine deiminase type-4-like
, HL-60 PAD
, PADI-H protein
, peptidyl arginine deiminase, type V
, protein-arginine deiminase type IV
, protein-arginine deiminase type-4
, PAD type IV
, peptidylarginine deiminase IV
, peptidyl arginine deiminase, type 4
, peptidylarginine deiminase type alpha